Konstantinos N. Lazaridis

Konstantinos N. Lazaridis

Auto-generated profile, based on publicly available information

Konstantinos N. Lazaridis

Division of Gastroenterology and Hepatology Mayo Clinic Rochester Minnesota USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
VGVinod K. Gupta
Vinod K. Gupta
MKMinsuk Kim
Minsuk Kim
UBUtpal Bakshi
Utpal Bakshi
KCKevin Y. Cunningham
Kevin Y. Cunningham
JDJohn M. Davis
John M. Davis
JSJaeyun Sung
Jaeyun Sung
Providing insight into one’s health status from a gut microbiome sample is an important clinical goal in current human microbiome research. Herein, we introduce the Gut Microbiome Health Index (GMHI), a biologically-interpretable mathematical formula for predicting the likelihood of disease independent of the clinical diagnosis. GMHI is formulated upon 50 microbial species associated with healthy gut ecosystems. These species are identified through a multi-study, integrative analysis on 4347 human stool metagenomes from 34 published studies across healthy and 12 different nonhealthy conditions, i.e., disease or abnormal bodyweight. When demonstrated on our population-scale meta-dataset, GMHI is the most robust and consistent predictor of disease presence (or absence) compared to α-diversity indices. Validation on 679 samples from 9 additional studies results in a balanced accuracy of 73.7% in distinguishing healthy from non-healthy groups. Our findings suggest that gut taxonomic signatures can predict health status, and highlight how data sharing efforts can provide broadly applicable discoveries.

19 December 2016 in Nature Genetics
Verified
Journal Article
Open access
PDF file
TCThe UK-PSC Consortium
The UK-PSC Consortium
SJSun-Gou Ji
Sun-Gou Ji
TCThe International IBD Genetics Consortium
The International IBD Genetics Consortium
TGThe International PSC Study Group
The International PSC Study Group
BJBrian D Juran
Brian D Juran
CACarl A Anderson
Carl A Anderson
Konstantinos Lazaridis, Carl Anderson and colleagues report results of a genome-wide association study of primary sclerosing cholangitis (PSC). They identify four new susceptibility loci for PSC and quantify the correlation of common genetic variation shared between PSC and inflammatory bowel diseases. Primary sclerosing cholangitis (PSC) is a rare progressive disorder leading to bile duct destruction; ∼75% of patients have comorbid inflammatory bowel disease (IBD). We undertook the largest genome-wide association study of PSC (4,796 cases and 19,955 population controls) and identified four new genome-wide significant loci. The most associated SNP at one locus affects splicing and expression of UBASH3A, with the protective allele (C) predicted to cause nonstop-mediated mRNA decay and lower expression of UBASH3A. Further analyses based on common variants suggested that the genome-wide genetic correlation (rG) between PSC and ulcerative colitis (UC) (rG = 0.29) was significantly greater than that between PSC and Crohn's disease (CD) (rG = 0.04) (P = 2.55 × 10−15). UC and CD were genetically more similar to each other (rG = 0.56) than either was to PSC (P < 1.0 × 10−15). Our study represents a substantial advance in understanding of the genetics of PSC.

6 March 2023 in Journal of Hepatology
Verified
Journal Article
Open access
RBRobert Barouki
Robert Barouki
MSMichel Samson
Michel Samson
EBEtienne Blanc
Etienne Blanc
MCMASSIMO Giuseppe COLOMBO
MASSIMO Giuseppe COLOMBO
JZJessica Zucman-Rossi
Jessica Zucman-Rossi
XCXavier Coumoul
Xavier Coumoul
Since the initial development of the exposome concept, much effort has been devoted to the characterisation of the exposome through analytical, epidemiological, and toxicological/mechanistic studies. There is now an urgent need to link the exposome to human diseases and to include exposomics in the characterisation of environment-linked pathologies together with genomics and other omics. Liver diseases are particularly well suited for such studies since major functions of the liver include the detection, detoxification, and elimination of xenobiotics, as well as inflammatory responses. It is well known that several liver diseases are associated with i) addictive behaviours such as alcohol consumption, smoking, and to a certain extent dietary imbalance and obesity, ii) viral and parasitic infections, and iii) exposure to toxins and occupational chemicals. Recent studies indicate that environmental exposures are also significantly associated with liver diseases, and these include air pollution (particulate matter and volatile chemicals), contaminants such as polyaromatic hydrocarbons, bisphenol A and per-and poly-fluorinated substances, and physical stressors such as radiation. Furthermore, microbial metabolites and the "gut-liver" axis play a major role in liver diseases. Exposomics is poised to play a major role in the field of liver pathology. Methodological advances such as the exposomics-metabolomics framework, the determination of risk factors' genomic and epigenomic signatures, and cross-species biological pathway analysis should further delineate the impact of the exposome on the liver, opening the way for improved prevention, as well as the identification of new biomarkers of exposure and effects, and additional therapeutic targets.

9 May 2018 in Hepatology
Verified
Journal Article
Closed access
PDF file
JEJohn E. Eaton
John E. Eaton
MVMette Vesterhus
Mette Vesterhus
BMBryan M. McCauley
Bryan M. McCauley
EAElizabeth J. Atkinson
Elizabeth J. Atkinson
ESErik M. Schlicht
Erik M. Schlicht
KLKonstantinos N. Lazaridis
Konstantinos N. Lazaridis

24 August 2007 in Hepatology
Verified
Journal Article
Open access
PDF file
KLKonstantinos N. Lazaridis
Konstantinos N. Lazaridis
BJBrian D. Juran
Brian D. Juran
GBGwen M. Boe
Gwen M. Boe
JSJoshua P. Slusser
Joshua P. Slusser
Mariza De AndradeMariza De Andrade
Mariza De Andrade
GPGloria M. Petersen
Gloria M. Petersen
Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disorder that can progress to cirrhosis, shortening life expectancy. PBC patients are often asymptomatic, present with biochemical cholestasis, and test positive (≥90%) for antimitochondrial antibodies (AMAs) in serum. Although AMA positivity without biochemical cholestasis may indicate increased risk of future PBC development, the contribution of these antibodies to pathogenesis remains enigmatic. Environmental risks and genetic determinants are likely implicated in PBC etiology. Given the familial aggregation of PBC, we hypothesized that AMAs also aggregate among relatives of PBC probands. We investigated the prevalence of AMAs in first-degree relatives (FDRs) of PBC probands to examine whether AMAs aggregate in such pedigrees. Using a PBC family registry, we prospectively screened for AMAs in the serum of 306 FDRs in 145 pedigrees, 350 PBC probands, and 196 controls who were age-matched, sex-matched, race-matched, and residence-matched to probands. The prevalence of AMA in FDRs and controls was 13.1% and 1%, respectively. Greater prevalence of AMA was found in female FDRs of PBC probands [sisters (20.7%), mothers (15.1%), and daughters (9.8%)] than in male FDRs [brothers (7.8%), fathers (3.7%), and sons (0%)]. Conclusions: AMAs aggregate among FDRs of PBC probands. Our data have clinical implications for FDRs of PBC probands because AMA positivity may suggest susceptibility to PBC. Thus, the identification and follow-up of these relatives may lead to earlier disease diagnosis and treatment. Furthermore, if AMA development is heritable, this trait will provide a basis to dissect the genetic predisposition to PBC. (Hepatology 2007.)

1 May 2016 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
AGAliya F Gulamhusein
Aliya F Gulamhusein
JEJohn E Eaton
John E Eaton
JTJames H Tabibian
James H Tabibian
EAElizabeth J Atkinson
Elizabeth J Atkinson
BJBrian D Juran
Brian D Juran
KLKonstantinos N Lazaridis
Konstantinos N Lazaridis
OBJECTIVES:Primary sclerosing cholangitis (PSC) often coexists with inflammatory bowel disease (IBD) and can be complicated by cholangiocarcinoma (CCA), a lethal malignancy for which reliable predictors remain unknown. We aimed to characterize the influence of colectomy and IBD duration on risk of C